Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial

By: Kimberly J. Perez · Andressa Dias Costa · Alexander Jordan · Thomas B. Karasic · Dalia Elganainy · Suryun Kim · Chen Yuan · Dan Y. Gui · Runzi Tan · Sung Chul Hong · Xi Wang · Simona Cristea · Emma Coleman · Morgan Truitt · Tae Gyu Oh · Hui Zheng · C. Sloane Furniss · Lauren Brais · Alexandra Bird · Josh Remland · Vasilena Gocheva · Jennifer S. Thalappillil · Mark Anderson · James M. Cleary · Andrea Enzinger · Marios Giannakis · Kimmie Ng · Douglas A. Rubinson · Benjamin Schlechter · Rishi Surana · Harshabad Singh · Thomas Abrams · Ursina Teitelbaum · Natallia Izgur · Eliezer Allen · Peter S. Winter · Srivatsan Raghavan · Jen Jen Yeh · Daniel Von Hoff · Christopher Liddle · Michael Downes · Ronald M. Evans · Peter O’Dwyer · Andrew Aguirre · Jonathan A. Nowak · Brian M. Wolpin

25 May 2026 at 08:00

Nature Cancer, Published online: 25 May 2026; doi:10.1038/s43018-026-01165-8

In this phase 2 trial, Perez et al. reported the safety of the vitamin D receptor agonist paricalcitol with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma and the pharmacodynamic effects of paricalcitol in fibroblasts and immune cells.

Reading view